Gilead closes in on second CAR-T approval in USThe FDA is due to decide by 10 August whether it will approve a second CAR-T therapy from Share XGilead closes in on second CAR-T approval in UShttps://pharmaphorum.com/news/gilead-closes-in-on-second-car-t-approval-in-us/
EMA starts review of second CAR-T from Gilead’s Kite unitThe EU regulator has started its review of a second CAR-T from Gilead Sciences’ Kite Pharma subsidiary, setting Share XEMA starts review of second CAR-T from Gilead’s Kite unithttps://pharmaphorum.com/news/ema-starts-review-of-second-car-t-from-gileads-kite-unit/
ViiV’s two-drug HIV therapy Dovato gets Japanese approvalOne of ViiV Healthcare’s two-drug HIV therapies – Dovato – has been approved in Japan, providing a new Share XViiV’s two-drug HIV therapy Dovato gets Japanese approvalhttps://pharmaphorum.com/news/viivs-two-drug-hiv-therapy-dovato-gets-japanese-approval/
Gilead says arthritis drug filgotinib fails in follow-up use trialsAs Gilead and Galapagos prepare their JAK inhibitor filgotinib for a US filing in rheumatoid arthritis, the drug Share XGilead says arthritis drug filgotinib fails in follow-up use trialshttps://pharmaphorum.com/news/gilead-says-arthritis-drug-filgotinib-fails-in-follow-up-use-trials/
Expect more M&A as Gilead names Dickinson as finance chief, say analystsGilead Sciences has named head of corporate development and strategy Andrew Dickinson as its new chief financial officer Share XExpect more M&A as Gilead names Dickinson as finance chief, say analystshttps://pharmaphorum.com/news/expect-more-ma-as-gilead-names-dickinson-as-finance-chief-say-analysts/
Humira tops list of drugs with unwarranted US price hikesAbbVie’s Humira heads a list of seven medicines that collectively contributed to a $5.1 billion increase in US Share XHumira tops list of drugs with unwarranted US price hikeshttps://pharmaphorum.com/news/humira-tops-list-of-drugs-with-unwarranted-us-price-hikes/
Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomaThe Scottish Medicines Consortium has backed NHS funding for Gilead’s CAR-T therapy Yescarta for B-cell lymphomas, a few Share XScotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphomahttps://pharmaphorum.com/news/scotland-says-yes-to-gileads-car-t-yescarta-for-lymphoma/
Gilead will challenge US government patent on PrEP drug TruvadaGilead Sciences has said it plans to challenge patents held by the US government on the use of Share XGilead will challenge US government patent on PrEP drug Truvadahttps://pharmaphorum.com/news/gilead-will-challenge-us-government-patent-on-prep-drug-truvada/
Gilead’s Descovy gets FDA panel OK for PrEP, but not for womenGilead’s Descovy got a green light from an FDA advisory committee for HIV pre-exposure prophylaxis (PrEP) yesterday – Share XGilead’s Descovy gets FDA panel OK for PrEP, but not for womenhttps://pharmaphorum.com/news/gileads-descovy-gets-fda-panel-ok-for-prep-but-not-for-women/
